Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
CONTEXT: Glioblastoma multiforme (GBM) is the most common malignant brain tumor originating in the central nervous system. Efficient delivery of therapeutic molecules to the cells and tissues is a difficult challenge. OBJECTIVE: Arginine-glycine-aspartic acid peptide (RGD)-modified nanostructured lipid carriers (NLCs) were used for the delivery of temozolomide (TMZ) into the GBM to provide a new paradigm in gliomatosis cerebri treatment. METHODS: RGD-conjugated polyethylene glycol-b-distearoylphosphatidylethanolamine (PEG-DSPE) was synthesized. RGD containing, TMZ-loaded NLCs (RGD-TMZ/NLCs) were prepared. Their particle size, zeta potential, drug encapsulation efficiency (EE) and drug release behavior were evaluated. In vitro cytotoxicity study of TMZ/NLCs was tested in U87 malignant glioma cells (U87MG cells). In vivo antitumor efficacy of the carriers was evaluated on mice bearing GBM model. RESULTS: The U87MG cells were successfully inhibited by RGD-TMZ/NLCs in vitro. RGD-TMZ/NLCs also displayed the highest antitumor efficacy in vivo than all the other formulations used for comparison. CONCLUSION: RGD-TMZ/NLCs were efficient in selective delivery of TMZ into U87MG cells, and inhibition efficacy is high. These RGD-modified vectors could be a superior drug delivery nano-system to achieve therapeutic efficacy, and this research could be a new promising strategy for treatment in malignant gliomatosis cerebri.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Xiao, H., Song, H., Yang, Q., Cai, H., Qi, R., Yan, L., Liu, S., Zheng, Y., Huang, Y., Liu, T., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.05.049 · Cited by 200 · cited 1×
“…drugs and the drug-loaded NLC-treated groups, two conclusions could be summarized as follows: (1) the containing of RGD was more effective than the use of non-RGD contained TMZ/NLCs. (2) The TMZ-loaded NLCs showed better antitumor effect compared with free drug (Xiao et al., 2012; Lv et al., 2014).”
BackgroundMannan-Modified Solid Lipid Nanoparticles for Targeted Gene Delivery to Alveolar Macrophages
Yu, W., Liu, C., Liu, Y., Zhang, N., & Xu, W. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0149-z · Cited by 137 · cited 1×
“Cytotoxicity deeply influenced the ability of the nanocarriers (Yu et al., 2010).”
Background
Cited by
Nanostructured lipid carriers for site-specific drug delivery
Khosa, A., Reddi, S., & Saha, R. N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.055 · Cited by 619
Tapeinos, C., Battaglini, M., & Ciofani, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.033 · Cited by 539
Zou, Y., Liu, Y., Yang, Z., Zhang, D., Lu, Y., Zheng, M., Xue, X., Geng, J., Chung, R., & Shi, B. (2018) · Advanced Materials · doi:10.1002/adma.201803717 · Cited by 203
Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy
Upton, D. H., Ung, C., George, S. M., Tsoli, M., Kavallaris, M., & Ziegler, D. S. (2022) · Theranostics · doi:10.7150/thno.69682 · Cited by 182
Chu, L., Wang, A., Ni, L., Yan, X., Song, Y., Zhao, M., Sun, K., Mu, H., Liu, S., Wu, Z., et al. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1494226 · Cited by 127
Metadata
- Authors
- Song, S., Mao, G., Du, J., & Zhu, X.
- Venue
- Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2015-07-23
- Volume
- 23
- Issue
- 4
- Pages
- 1404-1408
- ISSN
- 1071-7544 (ISSN-L)
- 1521-0464
- OpenAlex
- W1841201983
- Cited by
- 112
- References
- 2
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. https://app.cochat.ai/papers/10.3109/10717544.2015.1064186
- The paper
- Song, S., Mao, G., Du, J., & Zhu, X. (2016). Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. Drug Delivery. https://doi.org/10.3109/10717544.2015.1064186
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.